AEterna Zentaris (TSX:AEZS) EV-to-EBITDA

: 1.38 (As of Today)

View and export this data going back to 1995. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AEterna Zentaris's enterprise value is C$-33.31 Mil. AEterna Zentaris's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$-24.06 Mil. Therefore, AEterna Zentaris's EV-to-EBITDA for today is 1.38.

The historical rank and industry rank for AEterna Zentaris's EV-to-EBITDA or its related term are showing as below:

TSX:AEZS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.04 Med: -0.2 Max: 7.9
Current: 1.38

During the past 13 years, the highest EV-to-EBITDA of AEterna Zentaris was 7.90. The lowest was -14.04. And the median was -0.20.

TSX:AEZS's EV-to-EBITDA is ranked better than
63.5% of 474 companies
in the Biotechnology industry
Industry Median: 9.165 vs TSX:AEZS: 1.38

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-24), AEterna Zentaris's stock price is C$2.66. AEterna Zentaris's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-4.601. Therefore, AEterna Zentaris's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

AEterna Zentaris EV-to-EBITDA Historical Data

The historical data trend for AEterna Zentaris's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

Get a 7-Day Free Trial

-1.21

-0.62

2.58

2.32

1.37

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															2.32	2.20	2.00	1.71	1.37

Competitive Comparison

For the Biotechnology subindustry, AEterna Zentaris's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's EV-to-EBITDA falls into.

AEterna Zentaris EV-to-EBITDA Calculation

AEterna Zentaris's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	-33.307	/	-24.06
	=	1.38

AEterna Zentaris's current Enterprise Value is C$-33.31 Mil.
AEterna Zentaris's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-24.06 Mil.

AEterna Zentaris (TSX:AEZS) EV-to-EBITDA Explanation

AEterna Zentaris's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	2.66	/	-4.601
	=	At Loss

AEterna Zentaris's share price for today is C$2.66.
AEterna Zentaris's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.601.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

AEterna Zentaris EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.